Obesity drug maker Novo Nordisk forecast slower growth this year after Wegovy sales more than doubled in the final quarter of ...
11hon MSN
Ozempic and Wegovy maker Novo Nordisk quieted Wall Street’s concerns with its fourth-quarter results and 2025 outlook.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback